KRAS and cancer: Hotspot mutations that predominately occur in codons 12 and 13 result in defective KRAS GTPase activity, thus enhancing the abundance of the active GTP-bound state in cells to promote cancer cell proliferation and growth via multiple downstream effector pathways such as the RAF/MEK/ERK (MAPK) pathway.